CoChat

Evaluation of Bazedoxifene/Conjugated Estrogens for the Treatment of Menopausal Symptoms and Effects on Metabolic Parameters and Overall Safety Profile

Lobo, Rogerio A., Pinkerton, JoAnn V., Gass, Margery L. S., Dorin, Maxine H., Ronkin, Sheila, Pickar, James H., Constantine, Ginger · 2010 · Obstetrical & Gynecological Survey
Cited by 64

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Preclinical and clinical data on bazedoxifene (BZA), a new selective estrogen receptor modulator, showed that it prevented bone loss in postmenopausal women and suggested the added benefit of reducing vasomotor symptoms while minimizing or antagonizing stimulatory effects on the breast and uterus. In the efficacy phase of the Selective estrogens, Menopause, and Response to Therapy-1 trial, the results of which were summarized in the previous abstract, combination of BZA with conjugated estrogens (CEs) in a tissue-selective estrogen complex prevented bone loss in postmenopausal women. The present study, also part of the Selective estrogens, Menopause, and Response to Therapy-1 trial, was a multicenter, double-blind, placebo-, and active phase 3 trial evaluating the effects of BZA/CE on menopausal symptoms, metabolic parameters, and the overall safety profile in postmenopausal women. The participants were 3397 healthy postmenopausal women with an intact uterus who were receiving hormone therapy. Women were randomly assigned to receive single daily oral doses of 6 BZA/CE regimens (BZA [10, 20, or 40 mg], each with CE [0.625 or 0.45 mg]), raloxifene 60 mg or placebo for up to 2-years. Compared to the placebo, the BZA (20 mg)/CE (0.625 or 0.45 mg) regimen significantly reduced the frequency and severity of hot flushes and improved parameters of vaginal atrophy. All BZA/CE doses reduced the daily number of hot flushes at 12 weeks by at least 3-fold compared to the placebo (51.7%–85.7% vs. 17.1%). Two BZA/CE regimens (BZA 20 mg/CE 0.625 or 0.45 mg) were significantly more effective than placebo in reducing both the frequency and severity of hot flushes. All dose levels of BZA/CE were associated with improved lipid and homocysteine parameters but had no significant effect on carbohydrate metabolism. Overall changes in coagulation parameters were similar for the placebo and BZA/CE. No apparent differences were found between the BZA/CE and placebo with respect to breast pain and overall adverse events. These findings indicate that a tissue-selective estrogen complex combining BZA and CE is effective in treating symptoms associated with menopause, especially vasomotor symptoms and vaginal atrophy, without increasing the incidence of breast pain or overall adverse reactions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.ogx.0000367516.48912.6a

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 64

Metadata

Authors
Lobo, R. A., Pinkerton, J. V., Gass, M. L. S., Dorin, M. H., Ronkin, S., Pickar, J. H., & Constantine, G.
Venue
Obstetrical & Gynecological Survey
Published
2010-01
Volume
65
Issue
1
Pages
32
ISSN
0029-7828 (ISSN-L)
OpenAlex
W2069358279
Cited by
64
References
1
FWCI
4.57
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of Bazedoxifene/Conjugated Estrogens for the Treatment of Menopausal Symptoms and Effects on Metabolic Parameters and Overall Safety Profile. https://app.cochat.ai/papers/10.1097/01.ogx.0000367516.48912.6a
The paper
Lobo, R. A., Pinkerton, J. V., Gass, M. L. S., Dorin, M. H., Ronkin, S., Pickar, J. H., & Constantine, G. (2010). Evaluation of Bazedoxifene/Conjugated Estrogens for the Treatment of Menopausal Symptoms and Effects on Metabolic Parameters and Overall Safety Profile. Obstetrical & Gynecological Survey. https://doi.org/10.1097/01.ogx.0000367516.48912.6a

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.